Skip to main content
20th International Myeloma Workshop Main banner
Back

    Marc S. Raab, MD (he/him/his)

    Group leader
    Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany and Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
    69120 Heidelberg, Baden-Wurttemberg, Germany

    Prof. Dr. med. Marc S. Raab is a physician-scientist and Professor of Medicine at the Heidelberg University Medical Center (HUMC) and a Group Leader at the German Cancer Research Center (DKFZ). He trained in internal medicine and then specialized in hematology/oncology before spending more than three years as a postdoctoral fellow at the Dana-Farber Cancer Institute, Harvard Medical School, in Boston. He returned to Heidelberg as an attending physician in 2008 and his main research focus is on translational research and early clinical trials. In 2010, he was appointed head of the Max-Eder Unit - 'Experimental Therapies for Hematologic Malignancies' - at the German Cancer Research Center (DKFZ), which became the Translational Myeloma Research Group at DKFZ in 2018. He served also Clinical Director of the Multiple Myeloma Center in Heidelberg and Head of the associated early clinical trial program. In 2022, he was appointed as Director of the Heidelberg Myeloma Center at HUMC. He also serves as the Vice-Chair of the Board of Directors of the GMMG- study group.
    His current scientific focus is on exploring new avenues for targeted therapies, resistance mechanisms in refractory myeloma and understanding the immune microenvironment and its impact on novel antibody- and cell-based immunotherapies to facilitate personalized treatment approaches for patients in need.

    Presentation(s):